# EDGAR Filing Document

**Accession Number:** 0001857044
**File Stem:** 0001493152-23-008866
**Filing Date:** 2023-3
**Character Count:** 16577
**Document Hash:** 4155f8b9ba345b0861a9482a8f5fe30f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-008866.hdr.sgml**: 20230324

**ACCESSION NUMBER**: 0001493152-23-008866

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 8

**FILED AS OF DATE**: 20230324

**DATE AS OF CHANGE**: 20230324

**EFFECTIVENESS DATE**: 20230324

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Indaptus Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001857044
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 863158720
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270828
- **FILM NUMBER:** 23759969

**BUSINESS ADDRESS:**
- **STREET 1:** 3 COLUMBUS CIRCLE
- **STREET 2:** 15TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** (646) 427-2727

**MAIL ADDRESS:**
- **STREET 1:** 3 COLUMBUS CIRCLE
- **STREET 2:** 15TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Intec Parent Inc.
- **DATE OF NAME CHANGE:** 20210414

**As filed with the Securities and Exchange Commission on March 24, 2023**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form** **S-8**

**Registration Statement**

***Under***

***The Securities Act of 1933***

**Indaptus Therapeutics, Inc.**

**(Exact name of Registrant as specified in its charter)**

---

| | |
|:---|:---|
| Delaware | 86-3158720 |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(IRS Employer**<br> **Identification No.)** |
| 3 Columbus Circle<br> 15th Floor<br> New York, New York | 10019 |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan

**(Full title of the plan)**

Jeffrey A. Meckler

Chief Executive Officer

Indaptus Therapeutics, Inc.

3 Columbus Circle

15th Floor

New York, New York 10019

(646) 427-2727

**(Name and address of agent for service) (Telephone number, including area code, of agent for service)**

*With copies to:*

Peter N. Handrinos, Esq.

Latham & Watkins LLP

200 Clarendon Street

Boston, MA 02116

(617) 948-6000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,000,000 shares of the Registrant's common stock to be issued pursuant to the Indaptus Therapeutics, Inc. 2021 Equity Incentive Plan (the "Incentive Plan"). A Registration Statement of the Registrant on Form S-8 relating to the Incentive Plan is effective.

**INCORPORATION BY REFERENCE OF** 

**CONTENTS OF REGISTRATION STATEMENTS ON FORM S-8** 

The contents of the Registration Statement on Form S-8 (File No. [333-259127](https://www.sec.gov/Archives/edgar/data/1857044/000149315221021456/forms-8.htm)), including any amendments thereto, filed with the Securities and Exchange Commission, relating to the Incentive Plan, are incorporated herein by reference.

**Item 8. Exhibits**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 4.1 | <br> [Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc., dated as of July 23, 2021 (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed with the SEC on July 23, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221017640/ex3-1.htm) |
| 4.2 | [Amended and Restated Bylaws of Indaptus Therapeutics, Inc., dated as of July 23, 2021 (incorporated by reference to Exhibit 3.2 of the Company's Current Report on Form 8-K filed with the SEC on July 23, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221017640/ex3-2.htm) |
| 4.3<br>| [Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc. dated August 3, 2021 (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018935/ex3-1.htm) |
| 4.4 | [Amendment No. 1 to Amended and Restated Bylaws of Indaptus Therapeutics, Inc., dated as of July 20, 2022 (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed with the SEC on July 20, 2022)](https://www.sec.gov/Archives/edgar/data/1857044/000149315222020040/ex3-1.htm) |
| 5.1\* | [Opinion of Latham & Watkins LLP](ex5-1.htm) |
| 23.1\* | [Consent of Haskell & White LLP, Independent Registered Public Accounting Firm](ex23-1.htm) |
| 23.2\* | [Consent of Latham & Watkins LLP (included in Exhibit 5.1)](ex5-1.htm) |
| 24.1\* | [Power of Attorney (included on signature page)](#akl_001) |
| 99.1 | [Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company's Annual Report on Form 10-K filed with the SEC on March 17, 2023)](https://www.sec.gov/Archives/edgar/data/1857044/000149315223008010/ex10-1.htm) |
| 99.2 | [First Amendment to the Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 of the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/ex10-7.htm) |
| 107.1\* | [Filing fee Table](ex107.htm) |

---

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, New York on March 24, 2023.

---

| | |
|:---|:---|
| **INDAPTUS THERAPEUTICS, INC.** | **INDAPTUS THERAPEUTICS, INC.** |
| By: | */s/ Jeffrey A. Meckler* |
| Name: | Jeffrey A. Meckler |
| Title: | Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below hereby constitutes and appoints Jeffrey A. Meckler and Nir Sassi, or each of them singly, with full power to act without the other, such person's true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Jeffrey A. Meckler* | Chief Executive Officer and Director | March 24, 2023 |
| Jeffrey A. Meckler | (principal executive officer) |  |
| */s/ Nir Sassi* | Chief Financial Officer | March 24, 2023 |
| Nir Sassi | (principal financial and accounting officer) |  |
| */s/ Michael J. Newman, Ph.D.* | Chief Scientific Officer and Director | March 24, 2023 |
| Michael J. Newman, Ph.D. |  |  |
| */s/ Roger J. Pomerantz, M.D.* | Chairman of the Board of Directors | March 24, 2023 |
| Roger J. Pomerantz, M.D. |  |  |
| */s/ Mark J. Gilbert* | Director | March 24, 2023 |
| Mark J. Gilbert |  |  |
| */s/ William B. Hayes* | Director | March 24, 2023 |
| William B. Hayes |  |  |
| */s/ Hila Karah* | Director | March 24, 2023 |
| Hila Karah |  |  |
| */s/ Anthony J. Maddaluna* | Director | March 24, 2023 |
| Anthony J. Maddaluna |  |  |
| */s/ Robert E. Martell, M.D., Ph.D.* | Director | March 24, 2023 |
| Robert E. Martell, M.D., Ph.D. |  |  |
| */s/ Brian O'Callaghan* | Director | March 24, 2023 |
| Brian O'Callaghan |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | | |
|:---|:---|:---|
|  | 200 Clarendon Street | 200 Clarendon Street |
|  | Boston, Massachusetts 02116 | Boston, Massachusetts 02116 |
|  | Tel: +1.617.948.6000 Fax: +1.617.948.6001 | Tel: +1.617.948.6000 Fax: +1.617.948.6001 |
|  | www.lw.com | www.lw.com |
| ![](ex5-1_001.jpg)  | FIRM / AFFILIATE OFFICES | FIRM / AFFILIATE OFFICES |
|  | Austin | Milan |
|  | Beijing | Munich |
|  | Boston | New York |
|  | Brussels | Orange County |
|  | Century City | Paris |
|  | Chicago | Riyadh |
|  | Dubai | San Diego |
|  | Düsseldorf | San Francisco |
|  | Frankfurt | Seoul |
|  | Hamburg | Shanghai |
|  | Hong Kong | Silicon Valley |
|  | Houston | Singapore |
|  | London | Tel Aviv |
|  | Los Angeles | Tokyo |
|  | Madrid | Washington, D.C. |

---

March 24, 2023

Indaptus Therapeutics, Inc.

3 Columbus Circle, 15<sup>th</sup> Floor

New York, New York 10019

---

| | |
|:---|:---|
| Re: | <u>Registration Statement on Form S-8; 1,000,000 shares of Common Stock, par value $0.01 per share, of Indaptus Therapeutics, Inc.</u> |

---

To the addressee set forth above:

We have acted as special counsel to Indaptus Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the preparation and filing by the Company with the Securities and Exchange Commission of a registration statement on Form S–8 (the "<u>Registration Statement</u>") under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), relating to the issuance of up to 1,000,000 shares of the Company's common stock, par value $0.01 per share (the "<u>Shares</u>"), which may be issued pursuant to the Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan (as amended, the "<u>2021 Plan</u>"). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the prospectus forming a part thereof, other than as expressly stated herein with respect to the issuance of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon the foregoing and upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein only as to the General Corporation Law of the State of Delaware, as amended (the "<u>DGCL</u>"), and we express no opinion with respect to any other laws.

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the recipients thereof, and have been issued by the Company for legal consideration in excess of par value in the circumstances contemplated by the 2021 Plan, assuming in each case that the individual grants or awards under the 2021 Plan are duly authorized by all necessary corporate action and duly granted or awarded and exercised in accordance with the requirements of law and the 2021 Plan (and the agreements and awards duly adopted thereunder and in accordance therewith), the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

**March 24, 2023**

**Page 2**

![](ex5-1_002.jpg)

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Securities Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Securities and Exchange Commission thereunder.

---

| |
|:---|
| Sincerely, |
| /s/ Latham & Watkins LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

![](ex23-1_001.jpg)

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of Indaptus Therapeutics, Inc. (the "Company"), pertaining to the Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan, of our report dated March 16, 2023, relating to our audits of the Company's consolidated financial statements as of December 31, 2022 and 2021, and for each of the years then ended, included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission.

---

| | |
|:---|:---|
|  | */s/ Haskell & White LLP* |
|  | HASKELL & WHITE LLP |
| Irvine, California |  |
| March 24, 2023 |  |

---

![](ex23-1_002.jpg)

## Ex-Filing

**Exhibit 107.1**

**CALCULATION OF FILING FEE TABLE**

**FORM S-8**

(Form Type)

**INDAPTUS THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**<u>Table I: Newly Registered Securities</u>**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Plan** | **Security <br> Type** | **Security Class <br> Title** | **Fee <br> Calculation <br> Rule** | **Amount <br> Registered<sup>(1)</sup>** | **Proposed Maximum <br> Offering Price <br> Per Unit** | **Maximum <br> Aggregate Offering <br> Price** | **Fee Rate** | **Amount of <br> Registration Fee** |
| 2021 Stock Incentive Plan | Equity | Common Stock, par value $0.01 per share | Rule 457(c) <br> and 457(h) | 1000000<sup>(2)</sup> | $1.66<sup>(3)</sup> | $1660000 | $110.20 per million dollars | $182.93 |
|  | <br> **Total Offering Amounts** | <br> **Total Offering Amounts** | <br> **Total Offering Amounts** |  |  | $1660000 |  | $182.93 |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  | $— |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  |  | $182.93 |

---

(1) In
 accordance with Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement
 shall be deemed to cover any additional securities that may from time to time be offered or issued under the Indaptus Therapeutics,
 Inc. 2021 Stock Incentive Plan (as amended, the "Incentive Plan") to prevent dilution resulting from stock splits, stock
 dividends or similar transactions. In addition, pursuant to Rule 416(c) under the Securities Act, this registration statement also
 covers an indeterminate amount of interests to be offered or sold pursuant to the Incentive Plan.

(2) Consists
 of 1,000,000 shares of Common Stock that may become issuable under the Incentive Plan pursuant to its terms.

(3) Estimated
 solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as
 amended, and based upon the average of the high and low prices of the Common Stock as reported on the Nasdaq Capital Market on March
 21, 2023.